ERBB2 and breast cancer: Results of I-SPY2 trial investigating anti-LAG-3 and anti-PD1 in early-stage high risk HER2-negative BC, presented at SABCS 2022, showed a predicted pCR of 60% in patients with HR- HER2- disease, and 37% in patients with HR+ HER2- disease [55].